Skip to main content

Table 1 PD-L1 immunohistochemistry assays for clinical application

From: Clinical applications of PD-L1 bioassays for cancer immunotherapy

Agent Nivolumab Pembrolizumab Atezolizumab Durvalumab
Antibody 28-8 22C3 SP142 SP263
Isotype and host species Rabbit IgG Mouse IgG Rabbit IgG Rabbit IgG
Binding site Extracellular Extracellular Intracellular Intracellular
Cell scored Tumor cell Tumor cell Tumor cell Tumor cell
Tumor stroma Immune cell
Cutoffs 1, 5, or ≥10% ≥50% tumor cell 1, 5, or ≥10% ≥25%
≥1% stroma